Finanzen von NovaBridge Biosciences (NBP)NBPNovaBridge Biosciences

Evaluating the bottom line, NovaBridge Biosciences maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -37.95%, provide a clear picture of how effectively NBP converts its operational activities into shareholder value.

In the context of the broader market, NBP competes directly with industry leaders such as ABOS and CRBP. With a market capitalization of $226.67M, it holds a leading position in the sector. When comparing efficiency, NBP's gross margin of N/A stands against ABOS's N/A and CRBP's N/A. Such benchmarking helps identify whether NovaBridge Biosciences is trading at a premium or discount relative to its financial performance.

The company reported a net loss of $37.9 million for H1 2026, with an EPS of -0.14, reflecting increasing financial strain. Additionally, R&D expenses surged to $14.3 million, indicating heavy investment but also financial pressure.